A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This study was designed to compare the efficacy and safety of YL201 with Investigator\'s choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
Epistemonikos ID: 766706a5634613d93adb6a239f1bd1197d565847
First added on: Apr 17, 2025